Sermorelin has one placebo-controlled trial in adults that measured real outcomes rather than a lab value. It ran five months and enrolled nineteen people. It reported its results split by sex, and the split is not favorable to women [1]. That split rarely gets mentioned outside the raw citation. Here is what the trial found, what it did not test, and why a negative subgroup result in a nineteen-person study is a different claim from “does not work in women.”
What did the trial find in women?
Ten women and nine men, aged 55 to 71, were randomized to nightly sermorelin or placebo for five months in a single-blind design, each given the same weight-based dose [1]. See how that trial dose translates by body weight for the actual number. In plain terms, the outcomes split cleanly by sex. Skin thickness rose in both women and men. Lean body mass rose only in the men. Ratings of general well-being and of libido moved only in the men. Neither sleep quality nor bone density changed in either group. That is the entire adult outcome record this drug has. Nothing larger or more recent exists, and nobody has repeated the study in the twenty-nine years since. For the month-by-month timeline of what changed in that trial, see the full before-and-after read; the men’s side of the same trial is in sermorelin for men.
Why the split matters more than the headline claim
A seller page that advertises a “clinically studied” benefit is almost always leaning on this same trial, and it rarely says which sex saw which result. Lean body mass is the finding most often used to pitch sermorelin to a general audience, and it is a men-only finding. Well-being and libido are frequently implied as benefits for any adult, and both are men-only results in the published data. Skin thickness is the one outcome that held for both sexes, and it is rarely the headline claim on a seller’s page at all. For a fuller accounting of which sermorelin claims have any support behind them, see sermorelin’s marketing claims, ranked by evidence.
None of this means a woman taking sermorelin experiences nothing. It means the specific outcomes this one trial measured did not move for the ten women in it. A different outcome, a different dose, or a larger sample could produce a different result. Nobody has run that study.
What “not demonstrated” does not mean
Two different claims get collapsed into one another constantly in this category, and keeping them apart is the whole point of this page. “Sermorelin has not been shown to improve lean mass in women” is a statement about the evidence that exists. “Sermorelin does not work in women” is a statement about the drug itself, and this trial does not support it. A study of ten women, in one age band, at one dose, over five months, is not powered to rule out a benefit it never had the numbers to detect. A result that misses significance in a group that size can easily be a sample-size problem rather than a biological one. Absence of a finding in a small trial is not a finding of no effect — and conflating the two is exactly how a thin evidence base turns into a confident-sounding claim.
The honest position sits between the two extremes, and it is the one this trial actually supports: on the outcomes it tested, in the sample it enrolled, women did not show the benefits the men did. Whether a different protocol, dose or longer trial would move the numbers for women is genuinely unknown. It has not been quietly disproven; it has not been tested again at all.
What did the trial not test?
The 1997 study is also worth reading for its boundaries. Ten women is a small subgroup inside an already small trial, and a result that misses statistical significance in a group that size tells you as much about sample size as about biology. Five months is not a year; a slower-onset change would not have shown up in this design. The cohort was 55 to 71 years old specifically, so the trial says nothing about a premenopausal or younger group, and it did not stratify by menopausal status at all. It also tested exactly one dose. Nothing in the published literature says whether a different dose would close the sex gap, widen it, or leave it unchanged. See the full literature census behind this drug for how thin the surrounding record is.
Has sermorelin been tested in women alone?
A PubMed search combining sermorelin with women or female terms and a trial or randomized-controlled-trial filter, run September 14, 2026, returned zero records beyond the 1997 study already described here. A broader search for sermorelin and randomized trials, with no sex restriction, returns ten records total, ever indexed, across the drug’s entire published history — and only one of those ten is the adult outcome trial with real, non-biomarker endpoints described above. No sex-specific sermorelin trial in adult women exists in the published record as of this search. That is a gap in the literature, not a published negative result.
Do sellers offer a women-specific sermorelin plan?
Rarely. Almost every seller runs one product page and one intake regardless of the buyer’s sex. An exception is TRT Kingdom, which prices sermorelin at $233 a month for men and $199 for women on a three-month plan; it does not publish a different dose. A few clinics, such as Tyde Wellness, lean toward women’s health generally. That sits beside the trial result in a way worth naming: the marketing barely segments by sex, while the strongest evidence that does exist is heavily weighted toward one.
The takeaway
Sermorelin’s adult outcome evidence comes from a single trial. On the measures closest to what a buyer wants — lean mass, well-being, libido — that trial found benefit in men and not in the ten women enrolled. A shared benefit, skin thickness, showed up in both sexes. That is a genuine split, worth knowing before treating a seller’s general benefit claims as evenly supported across sexes. It is not evidence that sermorelin has no effect in women. It is evidence that the specific outcomes measured in one small trial were not observed in the ten women who took part in it. Readers comparing sellers against this evidence can see how each one is priced and positioned on the sermorelin-for-women board.